ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today the publication of a darinaparsin (Zinapar ® or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science. The publication, titled “Darinaparsin Is a Multivalent Chemotherapeutic Which Induces Incomplete Stress Response with Disruption of Microtubules and Shh Signaling,” was conducted by a Vanderbilt University Medical Center research team from the Departments of Cell and Developmental Biology, the Epithelial Biology Center, and Department of Surgery.
The study describes darinaparsin’s anti-cancer activity as a unique multivalent mitochondrial-targeting agent acting on cell stress induction, microtubule polymerization and sonic hedgehog signaling (“Shh”). The publication concludes that darinaparsin’s range of action against these multiple drivers of neoplastic cell proliferation may make this organic arsenical an effective therapy for multiple resistant solid and hematological malignancies. The publication is available online at http://dx.plos.org/10.1371/journal.pone.0027699.
Darinaparsin is currently in a Phase 1 study in solid tumors using an oral formulation.
About ZIOPHARM Oncology, Inc.:ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer therapeutics. The Company’s small molecule programs include: Palifosfamide (Zymafos ® or ZIO-201) is a novel DNA cross-linker in class with bendamustine, ifosfamide, and cyclophosphamide and is currently in a randomized, double-blinded, placebo-controlled Phase 3 trial with palifosfamide administered intravenously for the treatment of metastatic soft tissue sarcoma in the front-line setting. The Company is also currently conducting a Phase 1 study of palifosfamide in combination with standard of care for addressing small cell lung cancer; an oral form of palifosfamide continues in preclinical study. Darinaparsin (Zinapar ® or ZIO-101) is a novel mitochondrial- and hedgehog-targeted agent (organic arsenic) currently in a solid tumor Phase 1 study with oral administration and has been developed intravenously for the treatment of relapsed peripheral T-cell lymphoma. Indibulin (Zybulin™ or ZIO-301) is a novel, oral tubulin binding agent that is expected to have several potential benefits including oral dosing, application in multi-drug resistant tumors, no neuropathy and a quite tolerable toxicity profile. It is currently being studied in Phase 1/2 in metastatic breast cancer.